A comprehensive review on promising antiviral therapeutic candidates identified against main protease from SARS-CoV-2 through various computational methods

Ekampreet Singh, Rameez Jabeer Khan, Rajat Kumar Jha, Gizachew Muluneh Amera, Monika Jain, Rashmi Prabha Singh, Jayaraman Muthukumaran* and Amit Kumar Singh*

Abstract

Background: The COVID-19 pandemic caused by SARS-CoV-2 has shown an exponential trend of infected people across the planet. Crediting its virulent nature, it becomes imperative to identify potential therapeutic agents against the deadly virus. The 3-chymotrypsin-like protease (3CLpro) is a cysteine protease which causes the proteolysis of the replicase polyproteins to generate functional proteins, which is a crucial step for viral replication and infection. Computational methods have been applied in recent studies to identify promising inhibitors against 3CLpro to inhibit the viral activity.

Main body of the abstract: This review provides an overview of promising drug/lead candidates identified so far against 3CLpro through various in silico approaches such as structure-based virtual screening (SBVS), ligand-based virtual screening (LBVS) and drug-repurposing/drug-reprofiling/drug-retasking. Further, the drugs have been classified according to their chemical structures or biological activity into flavonoids, peptides, terpenes, quinolines, nucleoside and nucleotide analogues, protease inhibitors, phenalene and antibiotic derivatives. These are then individually discussed based on the various structural parameters namely estimated free energy of binding ($\Delta G$), key interacting residues, types of intermolecular interactions and structural stability of 3CLpro-ligand complexes obtained from the results of molecular dynamics (MD) simulations.

Conclusion: The review provides comprehensive information of potential inhibitors identified through several computational methods thus far against 3CLpro from SARS-CoV-2 and provides a better understanding of their interaction patterns and dynamic states of free and ligand-bound 3CLpro structures.

Keywords: 3CLpro, In silico, Inhibitors, Structure-based virtual screening (SBVS), Ligand-based virtual screening (LBVS), Drug-repurposing
Background
Coronaviruses are enveloped, positive-sense, single-stranded RNA viruses that can cause respiratory, enteric, hepatic and neurologic diseases in mammals and birds [1, 2]. They belong to the family coronaviridae, subfamily coronavirinae, and are classified into four genera, namely alpha, beta, gamma and delta [3]. Most members of this family are enzootic with only a few species that infect humans (alpha and beta coronaviruses) [4]. The following known coronaviruses, Human coronavirus NL63 (HCoV-NL63), Human coronavirus 229E (HCoV-229E), Human coronavirus OC43 (HCoV-OC43), Human coronavirus (HCoV-HKU1), Severe acute respiratory syndrome coronavirus (SARS-CoV), SARS-CoV-2 and Middle East respiratory syndrome coronavirus (MERS-CoV), are known to infect humans [4]. Out of the seven human infecting coronaviruses, some remain relatively harmless (229E, NL63, OC43, HKU1) causing respiratory tract infections while others such as SARS-CoV and MERS-CoV are known etiological agents for two epidemics in 2002 and 2012, respectively causing more than 10,000 cumulative cases [3]. The recent pandemic associated with COVID-19 caused by SARS-CoV-2 has shown an unprecedented trend in the number of cases with over 37 million infected and more than one million mortalities worldwide [5].

Coronaviruses possess the largest known viral genome ranging from 26 to 32 kb with unique replication machinery consisting of proteins to protect the viral genome and sequester it from the host’s immune system [2]. The viral genome features a 5′ cap and 3′ poly (A) tail that allows it to act as an mRNA for translation. The 5′ end contains a leader sequence and an untranslated region (UTR) followed by the replicase gene encoding within two Open Reading Frames (ORFs), the non-structural proteins (nsps) which occupy two-thirds of the genome [6]. The 3′ end of the genome contains the structural proteins, i.e. spike (S), membrane (M), envelope (E) and nucleocapsid (N), and the accessory proteins are interspersed throughout the genome [7]. The S glycoprotein mediates the entry of the virus into the host cell via binding of its receptor binding domain (RBD) to the angiotensin-converting enzyme 2 (ACE2), a membrane protein expressed in various organs mainly lungs, kidney and intestines [4, 8, 9]. The cleavage of S glycoprotein by membrane protease such as TMPRSS2 or by endosomal protease like cathepsin L is critical for viral entry into the host cell [9–11]. The E proteins are essential for virus assembly and formation of ion channels in the viral membrane [12, 13]. The N protein and viral RNA form the ribonucleoprotein and the M protein aids in viral assembly and stabilization of the N-RNA complex and helps in structural determination of the envelope [13–15].

The viral genome possesses ORFs that encode the replicase polyproteins that code for the non-structural proteins (nsps). The production of replicase proteins begins with the translation of two ORFs 1a and 1ab through a 1-ribosomal frameshift mechanism, which produces two polyproteins pp1a and pp1ab [16]. This is followed by proteolytic processing of polyproteins by two virally encoded cysteine proteases, papain-like protease (PLpro, nsp3) and 3C-like protease (3CLpro, nsp5) or Main protease (MPro), which are essential for the maturation of 16 nsps [17, 18]. Evidence suggests that these nsps form the replication-transcription complex, which is localized in endoplasmic reticulum-derived membrane forming a microenvironment for protection of the viral RNA [19]. These nsps include various proteins that perform a plethora of crucial activities essential for viral survival. The nsp12, an RNA-dependent RNA polymerase, is responsible for the synthesis of viral RNA and utilizes nsp7 and 8 as cofactors for enhanced functioning [20–22]. The viral helicase (nsp13) is critical for replication since it has the ability to unwind double-stranded DNA or RNA [23]. Several nsps such as nsp14 (N7-MTase) and nsp16 (2′-OMTase) are responsible for RNA modification and require nsp10 as a cofactor [24–26]. The nsp15, a uridylyl-specific endoribonuclease, is responsible for sequestering the viral genome from the host immune system [27]. Together, these nsps perform critical functions crucial for viral replication, expression and vitality.

The current pandemic situation has caused the scientific community to search for effective therapeutic methods against the virus in a time-sensitive fashion. One such approach popularly applied for the identification of potential therapeutic agents is through computational approaches. Various drug-like or lead-like candidates have been identified or repurposed against various drug target proteins of SARS-CoV-2 through a structure-based virtual screening, targeting these proteins essential for viral replication. One such target with indispensable activity towards replication and infection is 3CLpro which proteolytically cleaves 11 sites on pp1a and pp1ab for the production of replicase proteins, i.e. nsps [28]. This prerequisite property of 3CLpro for viral replication makes it an ideal and unique drug target for antiviral therapy.

This perspective dives into the inhibitors that have been identified against 3CLpro of SARS-CoV-2 through in silico approach in recent studies (Fig. 1). This review aims at providing a cumulative source of computationally identified promising drug-like or lead-like candidates against 3CLpro from SARS-CoV-2 which provides a better insight into the various computational drug discovery techniques such as structure-based virtual screening, ligand-based virtual screening, pharmacophore-based virtual screening, drug repurposing, molecular docking, quantitative
structure activity relationship (QSAR), quantitative structure property relationship (QSPR) and molecular dynamics simulations.

**Main text**

**3-Chymotrypsin-like protease (3CLpro)**

The maturation of coronaviruses involves an intricate proceeding of robust proteolytic processing of the replicase polyproteins to regulate viral gene expression and replication. The majority of cleavage events associated with the polyproteins are performed by the 3CLpro which begins with autolytic cleavage of itself followed by cleavage of 11 interdomain sites to generate functional proteins like a helicase, an exoribonuclease, an RNA-dependent RNA polymerase, an endoribonuclease and a 2′-OMTase [28, 29]. Several crystal studies elucidate the 33.8 kDa 3CLpro as a homodimer with the two protomers aligned at right angles to each other [30]. Each protomer comprises 306 amino acid residues and consists of three functional domains characteristic of 3CLpro. The domain I (residues 8–101) and II (residues 102–184) are antiparallel β-barrels representative of cysteine proteases of the chymotrypsin family [31]. The domain III contains an arrangement of five α helices into an antiparallel globular cluster connected to domain II via an extended loop region (residues: 185–200) [30, 31]. The substrate-binding site is the deep cleft between...
domain I and II lined by hydrophobic residues with the catalytic site present in the centre of the cleft [32].

**Active site and mechanism**

3CLpro features a unique Cys-His dyad (Cys145 and His41) as its catalytic residues and is surrounded by other residues which confer substrate specificity. The conservation of specificities of the substrate, i.e. N-terminal peptide of 3CLpro prefers Thr-Ser-Ala-Val-Leu-Gln as positions P6 to P1, which interact with the substrate-binding site residues [33–35]. In the S1 subsite, the imidazole side chain of conserved histidine residue interacts with the carboxamide side-chain of P1; this reaction is generally accepted to be conducive of specificity for glutamine residue at P1 [6, 32]. Strong hydrogen bonds between Gln-P1 and His163, Gln-P1 and Phe140 ensure suitable binding of the substrate into the S1 site [6, 36]. The side chain of Leu-P2 and Thr-P4 is stabilized by deep hydrophobic S2 and S4 subsite, respectively. Ser-P5 and Thr-P6 residues interact with Pro168 and Ala191 residues of the enzyme through van der Waals interactions [34, 35, 37]. On the C terminal side of the substrate, the P1' position is occupied by a small residue like Ala, Ser and Gly residues which directly interact with the S1' shallow subsite through van der Waals interactions [33]. A long side-chain leucine is accommodated by the hydrophilic S2' subsite of the protease [33]. These structural attributes primarily of the S1, S2 and S4 subsite (Fig. 2) of the protease are essential for substrate binding and have been exploited for drug designing and discovery against SARS-CoV-2 due to their crucial role in the activity of 3CLpro.

The catalytic mechanism of 3CLpro initiates with the deprotonation of thiol group of Cys145 residue followed by a nucleophilic attack of resulting Sulphur anion on the substrate carbonyl carbon [16, 38]. This step results in the release of a peptide product with an amide terminus and in concert His41 residue is restored to its deprotonated form [16, 17]. The penultimate step is the hydrolysis of the resultant thioester to release a carboxylic acid which then leads to the regeneration of the protease [16, 17, 39]. This process of hydrolysis of the substrate by a general acid-base mechanism defines the catalytic action of 3CLpro.

**Inhibition of 3CLpro**

A recent study dives into the inhibition of 3CLpro from SARS CoV-2 with the help of a computationally designed Michael acceptor inhibitor N3 (PubChem CID: 146025593) which has been known to show inhibitory activity towards several 3CLpro including those from SARS and MERS. Through molecular docking studies, it was found that N3 oriented in a suitable pose within the substrate-binding site [31]. The efficacy of this inhibitor was analysed with enzymatic assays which inferred that N3 is a potent time-dependent inhibitor of 3CLpro. The same study includes a structural elucidation of the 3CLpro with N3 complex at 2.1 Å, which expounds the interactions between the inhibitor and crystal structure.
of 3CLpro (PDB ID: 6 LU7). The $\text{Sy}$ atom of Cys145 residue forms a covalent bond with the $\beta \text{C}$ of the vinyl group of N3 confirming the addition of the Michael inhibitor. The lactam at P1 forms a hydrogen bond with His163 residue in the S1 subsite. At P2, the side chain of Leu residue inserts into the hydrophobic S2 subsite whereas the side chain of Val residue at P3 is solvent exposed indicating its ability to tolerate a variety of functional groups. Ala residue at P4 interacts with a small hydrophobic pocket while P5 and bulky benzene at S1 makes van der Waals interactions with residues. It is also evident that N3 makes multiple hydrogen bonds with the residues of the substrate binding pocket, which helps to lock the inhibitor into the pocket [31, 35].

Another study elucidates the interactions of the inhibitor carmofur with 3CLpro from SARS-CoV-2, which shows a similar trend where the fatty acid moiety of carmofur is linked to the $\text{Sy}$ atom of Cys145 residue through a covalent bond [40]. In both studies, it is evident that the inhibitors cause a covalent modification of the catalytic Cys145 residue of SARS-CoV-2’s 3CLpro. It is interesting to notice that the mechanism of covalent modification can be different. It is also of interest to notice that through superposition analysis of the structures of 3CLpro, it is observed that domain III and the surface loops appear to be the most variable regions [31]. However, the substrate-binding pockets present in the cleft between domain II and domain III are highly conserved which makes them an ideal and unique drug target for the designing of potential antiviral compounds that have potent inhibitory activity against the virus [31, 41].

**Potential inhibitors of 3CLpro from SARS-CoV-2**

Various compounds identified through in silico assisted virtual screening and drug repurposing, i.e. in silico approaches, have been delineated as potential inhibitors of the catalytic site of 3CLpro. In silico approach provides researchers with a method to design promising drug or lead candidates or repurpose the existing drugs that show inhibitory activity based on the rationale of structure-based drug design which targets the essential structural features of a protein and identifies the potent inhibitors based on the concept of estimated free energy of binding and the formation of various intermolecular interactions such as hydrogen bonds, hydrophobic interactions and van der Waals interactions. Several computational studies have been conducted to identify inhibitors against 3CLpro from SARS-CoV-2 through virtual screening of a library of synthetic and natural compounds (Table 1).

**Flavonoids**

These are a group of polyphenolic plant metabolites with a general structure consisting of two phenyl rings and a heterocyclic ring [64]. Various libraries of such phytochemicals have been computationally screened against 3CLpro, and promising molecules have been identified [42-44, 46]. One such molecule, $5,7,3',4'-$Tetrahydroxy-2'-(3,3-dimethylallyl) isoflavone, displayed a binding affinity of $-29.57$ kcal/mol when docked using molecular operating environment (MOE) with 3CLpro (PDB Id: 6 LU7) through hydrogen bonding residues namely His41, Phe140, Gly143 and Glu166 and hydrophobic interactions with other key substrate residues [42]. Another study identified Cyanidin 3-glucoside as an inhibitor with an estimated binding free energy of $-8.40$ kcal/mol using Autodock Vina [65]; it forms six hydrogen bonds and three hydrophobic interactions, one of which is with the catalytic Cys145 residue [43]. In the same study, Bicalin interacts with 3CLpro through one hydrophobic interaction, six hydrogen bonds, one pi-sulphur interaction with the catalytic Cys145 residue, whereas Glabridin forms one electrostatic and five hydrophobic interactions. Interestingly, both Bicalin and Glabridin show a similar estimated binding free energy of $-8.10$ kcal/mol. Another flavonoid Quercetin 3-vicianoside interacts with His163, Glu166, Ser144, Leu114, Gly143 and Thr26 residues through hydrogen bonding and shows hydrophobic interactions with ten key residues and showed binding free energy of $-8.30$ kcal/mol [44]. Myricitrin, an anti-tussive molecule, through ADME analysis showed high solubility and bioavailability and displayed an estimated binding free energy of $-8.9$ kcal/mol through Autodock Vina [65]. The catalytic residues such as His41 and Cys145 interacted with a pi-alkyl and pi-sulphur bond with the aromatic scaffold of the ligand. It shows six hydrogen bonds with additional van der Waals interactions that stabilize the interaction between protein and ligand [45]. In a drug repurposing study, Oolonghomobisflavan-A molecule identified from tea plant showed minimum binding free energy from molecular mechanics Poisson–Boltzmann surface area (MM-PBSA) and a CDOCKER [66] interaction energy of 75.54 kcal/mol. It was observed to manifest seven hydrogen and several other stabilizing van der Waals interactions. The evaluation of MD simulations results showed that it was able to show strong interaction and higher stability with the binding pocket of 3CLpro and also had the potential to affect the dimerization of the protease [46]. The results of such molecular docking studies have delineated flavonoids as potent inhibitors against 3CLPro from SARS-CoV-2.

**Peptides**

Several drug molecules have been identified against 3CLpro which sports the chemical structure typical of a peptide classifying them as peptide inhibitors. Birinapant is one such drug, a peptidomimetic small molecule
| S/No | PubChem CID | Binding free energy (kcal/mol) | Tools used | Interacting residues | Refs |
|------|------------|--------------------------------|------------|---------------------|------|
| 1    | 5,7,3',4',5'-Tetrahydroxy-2',3,3' -dimethylallyl) isoflavone(11610052) | −29.57 | Molecular operating environment (MOE) | Thr25, Thr26, Leu26, His41, Val42, Ser46, Met49, Tyr54, Leu141, Asn142, Gly143, Ser144, Cys145, His163, His164, Met165, Glu166, Leu167, Pro168, Asp187, Arg188, Gln189, Thr190, Ala191, Gln192 | [42] |
| 2    | Cyanidin 3-glucoside(197081) | −8.4 | Autodock Vina | Glu166, Asn142, His163, Gln189, Asp187, Thr26, Met49, Gly143, His164, Gln189, Cys145 | [43] |
| 3    | Baicalin(64982) | −8.1 | Autodock Vina | Gly143, Leu141, Gln189, Met165, Asn142, Glu166, Pro168 | [43] |
| 4    | Glabridin(124052) | −8.1 | Autodock Vina | Leu141, Gly143, Cys145, His164, Gln189, Met165, Ser144, Thr26 | [43] |
| 5    | Quercetin 3-vicianoside(44259139) | −8.3 | Autodock Vina | His163, Gly143, Thr25, Asn142, Phe140, Cys145, Met165, His164, Leu141, Arg188, Gln189, Asp187, Met49, His41 | [44] |
| 6    | Myricitrin(5281673) | −8.9 | Autodock Vina | Tyr54, Asp187, Arg188, Leu141, Phe140, His172, Glu166, Ser144, His164, Met165, Met49, His41 | [45] |
| 7    | Oolonghomobisflavan-A(14520989) | −75.5 | CDOCKER | Thr25, Asn142, His163, Glu166, Gln192, Asn142, Gln189, His41 | [46] |
| 8    | Birinapant(49836020) | −8.1 | Glide Schrodinger Suite | Thr25, Thr26, Leu26, His41, Val42, Ser46, Met49, Met165, Ser144, His164, Met165, Glu166, Leu167, Pro168, Asp187, Arg188, Gln189, Thr190, Ala191, Gln192 | [47] |
| 9    | Carfilzomib(11556711) | −8.6 | Glide Schrodinger Suite | Cys145, His164, Gln166, Gln189, Asn142, Glu169, His41 | [48] |
| 10   | 6-Oxoisooxysteganin(21575473) | −9.1 | Autodock Vina | Arg189, Met49, Met165, Cys145 | [49] |
| 11   | 22-Hydroxyhopan-3-one(21582894) | −8.6 | Autodock Vina | Arg189, Met49, Met165, Cys145 | [49] |
| 12   | Crocin(5281233) | −8.2 | Autodock 1.5.4 tools | Thr135, Asn133, Thr199, Lys137, Lys5, Phe3, Arg4, Arg131, Asp197 | [50] |
| 13   | Carnosol(442009) | −8.2 | Autodock 1.5.6 tools | Cys145, His164, Glu166, Gln189, Met165, Arg188, Cys44, Met49, His41, Thr45, Thr25, Thr26, Leu27, Gly143, Ser46, Asn142 | [51] |
| 14   | Rosmanol(13966122) | −7.9 | Autodock 1.5.6 tools | Cys145, Gly143, Thr25, His41, Met49, Asn142, Gly143, His164, Leu141, Ser144, Met165, Met49, His41 | [51] |
| 15   | Withanone(21679027) | −4.4 | Glide Schrodinger Suite | Thr24, Thr25, Thr26, Leu27, His41, Met49, Tyr54, Asn142, Gly143, His164, Met165, Glu166, Arg188, Asp187, Gln189, Cys145 | [52] |
| 16   | Nelfinavir(64143) | −4.4 | Glide Schrodinger Suite | His163, Gln189 | [53] |
| 17   | CMPD23B | −118.6 | Igemdock | Arg40, Tyr54, Cys85, Phe181, Arg188, Arg40, Tyr54, Gly55, Met82, Asn84 | [54] |
| 18   | Amodiaquine(2165) | −7.4 | Glide Schrodinger Suite | Leu141, Arg187, Glu166, His41 | [55] |
| 19   | Remdesivir(121304016) | −7.9 | Glide Schrodinger Suite | Gln191, Ala192, Thr190, Gln189, Arg188, Asp187, Leu141, Asn142, Gly143, Ser144, Cys145, His164, Met165, Glu166, Leu167, Pro168, Thr26, Leu27, Met49, Tyr54, His41 | [56] |
| 20   | Ribavirin(37542) | −10.8 | MMPBSA.py module of AMBER16 | Met49, Met165, Pro168, Gln189, His41, Ala46, Met49, Glu166, Leu167, Leu187, Gln189, Ala191, Ala193 | [58] |
| 21   | Telbivudine(159269) | −14.9 | MMPBSA.py module of AMBER16 | Leu27, His41, Met49, Phe140, Asn142, Gly143, His164, Met165, Glu166, Asn142, Gly143, Ser144, Cys145, Met165, Glu166, Asp187, Gln189 | [58] |
| 22   | Saquinavir(441243) | −9.8 | Glide Schrodinger Suite | His41, Cys44, Tyr54, Met49, His172, Glu166, Met165, His164, His163, Phe140, Leu141, Asn142, Gly143, Ser144, Cys145, Thr25, Thr26, Leu27, Asp187, Arg188, Gln189, Thr190, Ala191 | [58] |
| 23   | Ritonavir(392622) | −10.8 | MMPBSA.py module of AMBER16 | Met49, Met165, Pro168, Ritonavir, His41, Ala46, Met49, Glu166, Leu167, Leu187, Gln189, Ala191, Ala193 | [58] |
| 24   | Simeprevir(24873435) | −10 | Autodock Vina | Glu166, Met165, Gln189, Phe140, Cys145, Asn142, Leu27, His41, Ser46 | [59] |
which displays a docking score of –8.14 using VS Workflow of Glide Schrodinger Suite and MM-GBSA binding free energy of –105.15 kcal/mol and forms a hydrogen bond with catalytic Cys145 residue [47]. MD simulation analysis performed using Desmond v3.6 module [67] highlighted that Birinapant granted maximum stability to the protein through hydrogen bonds appearing at hot spot residues in the proceeding of the simulation. Carfilzomib is a tetrapeptide epoxiketone and an approved anticancer drug. It has also been repurposed in computational studies as an inhibitor for 3CLpro showing a docking score of –8.6 using Glide flexible docking [68] and an MM-PBSA-WSAS binding free energy of –13.8 kcal/mol, and in conjugation, the MD trajectories from RMSD (root-mean-square deviation) fluctuation analysis show overall stability [48].

Terpenes

Terpenes constitute a large hydrocarbon class constructed from five-carbon isoprene units which are combined in a great variety of skeletons [69]. 6-Oxoisouguesterin, a bisnorterpenes, displayed a binding affinity of –9.1 kcal/mol using Autodock Vina 4.2 [65] when docked against 3CLpro (PDB ID: 6 LU7) of SARS-CoV-2 [49]. It formed a conventional hydrogen bond with Arg189 residue and created an alkyl and pi-alkyl stacking with Met49, Met165 and Cys145 residues. Another terpenoid 22-Hydroxypolypen-3-one had a binding affinity of –8.6 kcal/mol with one hydrogen bond to Lys137 residue and alkyl, pi-alkyl interaction with Leu287, Leu286, Leu286 and Tyr239 residues [49]. The ADME parameters of both the drugs indicate them to be non-carcinogenic, low toxicity and aqueous solubility of < 0, which shows them to be promising inhibitors. A library of therapeutic compounds from Moroccan medicinal plants was computationally investigated against 3CLpro (PDB ID: 6 LU7) which identified Crocin (binding free energy –8.20 kcal/mol), a carotenoid pigment of saffron forming eight hydrogen bonds, two alkyl attractions, two carbon-hydrogen bonds, and attractive charge interactions [50]. Another study of chemical compounds from Indian spices analysed two diterpenes Carnosol (ΔG = 8.20 kcal/mol) and Rosmanol (ΔG = 7.99 kcal/mol) showing stable estimated binding affinity (Raccoon and MGLTools-1.5.6 software by Autodock [70]) and ADME properties. When docked against 3CLpro (PDB ID: 6Y84), both drugs showed interactions with the active site residues, and MD simulation (Desmond package by Schrodinger [67]) of 50 ns inferred strong hydrogen bonding interactions and stronger stability of the protein-ligand complex [51]. Another study found Withanone, an active withanolide of W. somnifera, displayed active binding to the substrate pocket of 3CLpro and showed binding free energy of 34.51 ± 9.63 kcal/mol from MM/GBSA (molecular mechanics/generalized born surface area) and a Glide flexible docking score of -4.42. Forming one hydrogen bond with the catalytic Cys145 residue, several hydrophobic interactions, pi-pi stacking with several key residues and in the dynamic state through MD simulations using Desmond [67] with OPLS3e force field from Schrodinger it showed nine hydrogen bonds [71] (including one with His41 residue) and several other stabilizing interactions which assist to its efficacy as a promising inhibitor [52]. These studies indicate a variety of chemical compounds derived from natural sources that inhibit the activity of the viral protease in a virtual setting aiding the supposition of these compounds as promising inhibitors.
**Quinolines**

These compounds have a characteristic structure of a benzene ring fused with a pyridine making it a double-ringed heterocyclic aromatic organic compound [72]. Nelfinavir, an antiretroviral drug, is an isquinoline that has been studied profoundly for its activity against 3CLpro from SARS-CoV-2. In one in silico study, it shows an estimated binding affinity of −7.0 kcal/mol using Autodock Vina [65]. Through two independent MD simulations (IBM Power-cluster), it is observed that nelfinavir occupies almost the whole catalytic pocket of 3CLpro and is stabilized through internal hydrogen bonds, two hydrogen bonds with His163, Gln189 residues and significant hydrophobic interactions [53]. A library of noscapine and its derivatives was screened against 3CLpro (PDB ID: 6LU7) in which CMPD23B was identified as a potent virtual inhibitor showing efficient binding free energy and stabilizing interactions [54]. Another study identified Amodiaquine, an antimalarial aminoquinoline showing a docking score of −7.42 kcal/mol (Glide Module), formed four hydrogen bonds with Leu141, Arg187 residues and salt bridge interaction with Glu166 residue and a pi-pi stacking with catalytic His41 residue [55].

**Nucleoside and nucleotide analogues**

A popularly identified drug molecule against 3CLpro from SARS-CoV-2 through in silico methods is Remdesivir, an adenosine triphosphate analogue with potential antiviral activity against several RNA viruses. In one study, it showed a binding score of −7.9 using Covdock-Schrodinger suite (covalent docking module) [73] and MM/GBSA binding free energy of −65.19 kcal/mol, forming a covalent, irreversible bond with the catalytic Cys145 residue and three hydrogen bonds with several other stabilizing interactions. An MD simulation of 50 ns using GROMACS 2018.1 showed a significant decrease in the RMSD value of 3CLpro, RMSF (root-mean-square fluctuation) analysis shows reducing the flexibility of protein backbone, Rg (radius of gyration) values were in agreement with the previous results, and PCA (principal component analysis) inferred the higher stability of drug bound protein [56]. Another virtual screening study using Schrodinger glide docking module [68] identified two nucleoside analogues Ribavirin, an antiviral for hepatitis C, and Telbivudine, an antiviral for hepatitis B, as likely inhibitors of 3CLpro [57].

**Protease inhibitor**

In various recent computational endeavours, protease inhibitors of different viruses such as HIV, MHV, hepatitis C and SARS-CoV, have been virtually screened against 3CL protease of SARS-CoV-2. Undoubtedly, two drugs, namely lopinavir and ritonavir, have been studied because of their past clinical relevance with SARS and MERS. Both are HIV-1 protease inhibitors with known antiviral activity and have hence served as potential drugs in various studies and even been used as control drugs in other studies [74–76]. In one specific study, the binding free energy prediction by MM/PBSA using MMPBSA.py module of AMBER16 [77] for lopinavir and ritonavir was found to be −10.89 and −14.93 kcal/mol, respectively. MM/GBSA using MMGBSA.py module of AMBER16 [77] gave a value of −13.83 kcal/mol for lopinavir and −27.28 kcal/mol for ritonavir in binding free energy calculations. Through residue binding free energy calculation, key residues were identified for binding of the drugs to the catalytic site of 3CLpro. Four residues (Met49, Met165, Pro168 and Gln189) and nine residues (Leu27, His41, Met49, Phe140, Asn142, Gly143, His164, Met165 and Glu166) were important for the binding of lopinavir and ritonavir, respectively. MD simulations in the studies are conducive of robust binding between the ligands and the binding site of 3CLpro, indicating them as promising drugs against SARS-CoV-2 [58]. In another study, Saquinavir, an antiretroviral protease inhibitor of HIV/AIDS, was found to have a docking score of −9.85 using Covdock by Schrodinger suite and displayed binding energy of −72.17 kcal/mol through MM/GBSA calculations. It was found to make a covalent bond with catalytic Cys145 residue and five hydrogen bonds with binding pocket residues of 3CLpro. In MD simulations (using GROMACS 2018.1) of the protein-drug complex, it was found that there was a significant decrease in the RMSD value (0.039 Å) of 3CLpro when bound with the drug and also shows that binding of Saquinavir led to diminished fluctuations in the protein backbone. Throughout the simulation, Saquinavir showed average hydrogen bonding of 2, and through PCA, it was observed that it reduced the trace of covariance value to a lower degree of functional motions [56]. Moreover, this was additionally supported that this specific drug molecule increases the stability of 3CLpro. Another study identified Simeprevir with estimated binding free energy value (using Auto Dock Vina) of −10.0 kcal/mol with three hydrogen bonds (Glu166, Gly143 and Asn142 residues) [59]. A drug repurposing study identified Paritaprevir, a protease inhibitor of HCV, with an estimated binding free energy of −9.8 kcal/mol using PyRx v0.8 [78]. Paritaprevir formed one hydrogen bond with Ser46 residue and four pi interactions (including one with catalytic Cys145 residue) and van der Waal interactions. The MD simulation of the protein-drug complex performed using GROMACS 2019 implicated that Paritaprevir maintained the structural stability and integrity of 3CLpro, the catalytic dyad remains highly stable, and a maximum of six hydrogen bonds was observed in the proceeding of the simulation. PCA inferred that protein was more flexible during its affiliation with the drug; this along
with other parameters delineates Paritaprevir as a promising inhibitor against 3CLpro [60].

**Phenalene**

Hypericin is an antidepressant with a potent antiviral activity that sports a structural scaffold of phenalenone. It shows a binding affinity of \(-10.7\) kcal/mol (CDocker [79]) and manifests a pi-alkyl interaction with catalytic residue Cys145, four hydrogen bonds and five hydrophobic interactions with 3CLpro structure (PDB ID: 6 LU7). MD simulations performed using GROMACS version 5.1 observed induced local flexibility of key active residues when hypericin is bound to the protein. Other MD parameters corroborate the prediction of significant inhibition of 3CLpro by hypericin [43].

**Antibiotic derivatives**

Another series of drugs for inhibition of 3CLpro is antibiotic derivatives which have been repurposed in several studies. Eravacycline is a synthetic halogenated tetracycline antibiotic [80], and valrubicin is a chemotherapeutic drug which is a derivative of anthracycline antibiotic (doxorubicin) [81]. In a study, Eravacycline had a docking score of \(-8.8\) while valrubicin showed a docking score of \(-9.2\) when Glide flexible docking [68] was performed. The MD simulations of both the protein-drug complexes showed stable interactions [48]. Another study identified Viomycin, a tuberactinomycin antibiotic, formed eight hydrogen bonds with 3CLpro (PDB ID: 6 LU7) during docking studies with a CDocker energy of 77.29 kcal/mol. Allosteric binding of the drug was studied by a 100 ns MD simulation which indicated low RMSD values aiding to the stability of the protein-ligand complex. Interaction studies show Viomycin forming eight H-bonds with key substrate binding site residues and a residue responsible for dimerization (Phe140) [61]. These derivatives, along with others, represent a strong class of promising inhibitors for 3CLPro against SARS-CoV-2.

**Imidazole**

Compounds containing a five-carbon aromatic ring with nitrogen atoms at 1,3 positions are classified as imidazoles [82]. Elbasvir is a known direct acting antiviral used for the treatment of hepatitis C virus (HCV) [83]. A recent docking study of elbasvir displayed a glide score of \(-9.9\) with significant interactions with Thr25, Thr26, His41, Met49, Met165, Gln189 and Thr190 residues. The MM-GBSA binding free energy decomposition was performed to identify hot spots which included the catalytic His41 and Gln189 residues. An RMSD analysis of Elbasvir-3CLpro complex showed a stable structural pattern throughout the MD simulation [48].

**Indoles**

Compounds classified as indoles are characterized with a benzene ring fused with pyrrole ring [84]. In a recent study, Fluvastatin displayed a binding affinity of \(-7.7\) kcal/mol with significant interactions with Glu166 and His163 residues. Another similar study explored the binding score of Methisazone with 3CLpro (PDB Id: 5R80) through Glide flexible docking, which displayed a score of \(-6.8\). The hydroxyl group of the ligand formed H-bond with Glu166 residue, another H-bond, was formed between Thr190 and -NH$_2$ of ligand. The indole moiety of Methisazone displayed pi-pi stacking with His41 residue [63].

**Conclusion**

The high transmission rate of SARS-CoV-2 has led to the current COVID-19 pandemic with infections in over 188 countries/regions and over a million fatalities worldwide. This virulent attribute of the virus has led to fastidious research endeavours to find effective and potent inhibitors of the virus. While clinical trials for an ideal vaccine continue, it is crucial to identify alternative antiviral candidates to keep the virus from spreading any further. As traditional drug discovery is a long and laborious task, a repurposing approach has been applied by various researchers to identify potential inhibitors of SARS-CoV-2. Computer aided drug discovery has been robustly used to identify potential inhibitors to molecular targets of SARS-CoV-2. Such computational methods are excellent priming steps in drug discovery as they help propose a promising target and in conjunction with molecular dynamics simulations and more recently with artificial intelligence, the effectiveness of drugs can be predicted. It is important to note that in vivo studies in conjunction with in silico analysis are essential to understand the biological relevance of a promising drug candidate. Computational approaches effectively reduce the screening time and help in lead identification.

Out of the various targets of SARS-CoV-2, the 3CLpro is evidently one of the most investigated viral protein. The 3CLpro is responsible for proteolysis of the viral replicate polyproteins that produce the proteins essential for the viral life cycle. This indispensable activity makes it an attractive target for inhibition studies. Virtual screening studies of various molecules have shown high levels of binding affinities, and these results have often been corroborated with molecular dynamics studies. The compounds reviewed in the study showed appreciable screening results and interacted with key residues that are essential for the activity of 3CLpro. Interaction studies of the compounds show that the ligands effectively interacted with the catalytic subsites of 3CLpro.
including critical residues like His41, Cys145, Gln189, Glu166, Asn142 and Met 49 residues. These results help present data that can be applied to further extensive experimental analysis that can aid in the identification or discovery of a lead agent for inhibition of 3CLpro.

The present study extensively analyses research literature to report a comprehensive insight into the computational studies that are being carried out presently to identify potential candidates against 3CLpro. Moreover, the present study focused on the comprehensive collection of potential and promising drug or lead candidates against 3CLpro from SARS-CoV-2, which are identified by using various in silico techniques. Our on-going and future works are directed towards to collect the experimental details of promising molecules reported so far against 3CLpro from SARS-CoV-2. As the research regarding SARS-CoV-2 continues to grow in an unprecedented fashion, this review study aims to present critical data coherently to create an inclusive report of current research studies.

Abbreviations
SARS-CoV-2: Severe acute respiratory syndrome 2; COVID-19: Coronavirus disease; 3CLpro: 3-Chymotrypsin like protease; Mpro: Main protease; MD: Molecular dynamics simulation; MM-PSA: Molecular mechanics Poisson–Boltzmann surface area; MM/GBSA: Molecular mechanics generalized born surface area; RMSD: Root-mean-square deviation; RMSF: Root-mean-square fluctuation; Rt: Radius of gyration; PCA: Principal component analysis.

Acknowledgements
Dr. Amit Kumar Singh thanks the Department of Science and Technology (DST), Indian National Science Academy (INSA), Indian Council of Medical Research (ICMR) New Delhi, India. Gashaw Muluneh Amecha thanks the College of Natural Science, Wollo University, Dessie, Ethiopia. The authors thank Sharda University, Greater Noida, India, for the support.

Authors’ contributions
AKS and JM conceived the concept of the study. ES wrote the manuscript. ES and RJK prepared the figures and tables. ES, RJK, RKJ and GMA collected the literatures from various resources. MJ, RPS, JM and AKS corrected the manuscript. All authors approved the contents of the manuscript.

Funding
Not applicable

Availability of data and materials
All data generated or analysed during this study are included in this manuscript.

Ethics approval and consent to participate
Not applicable

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Biotechnology, School of Engineering and Technology, Sharda University, Greater Noida, U.P P.C. 201310, India. 2 Department of Biotechnology, IILM College of Engineering & Technology, Greater Noida, U.P, India.

Received: 5 August 2020 Accepted: 14 October 2020
Published online: 03 November 2020

References
1. Zhu N et al (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382(8):727–733
2. Lu R et al (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395(10244):565–574
3. de Wilde AH et al (2018) Host factors in coronavirus replication. Curr Top Microbiol Immunol 419:1–42
4. Vellingiri B et al (2020) COVID-19: a promising cure for the global panic. Sci Total Environ 725:138277
5. Dong E, Du H, Gardner L (2020) An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 20(5):S33–S34
6. Zebubur J, Snijder EJ, Gorbalenya AE (2000) Virus-encoded proteases and proteolytic processing in the Nidovirales. J Gen Virol 81(Pt 4):853–879
7. Fehr AR, Perlman S (2015) Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 1282:1–23
8. Andersen KG et al (2020) The proximal origin of SARS-CoV-2. Nat Med 26(4):450–452
9. Tang T et al (2020) Coronavirus membrane fusion mechanism offers a potential target for antiviral development. Antivir Res 178:104792
10. Hoffmann M et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2):271–280 e8
11. Ou X et al (2020) Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun 11(1):1620
12. Ruch TR, Machamer CE (2012) The coronavirus E protein: assembly and beyond. Viruses 4(3):363–382
13. Kandeel M et al (2020) From SARS and MERS CoVs to SARS-CoV-2: moving toward more biased codon usage in viral structural and nonstructural genes. J Med Virol 92(6):660–666
14. Astuti I, Ysrafil (2020) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response. Diabetes Metab Syndr 14(4):407–412
15. Huang J et al (2020) Pharmacological therapies targeting RNA-dependent RNA polymerase, protease and spike protein: from mechanistic studies to clinical trials for COVID-19. J Clin Med 9(4)
16. Pillayar T et al (2016) An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy. J Med Chem 59(14):6595–6628
17. Hsu MF et al (2005) Mechanism of the maturation process of SARS-CoV 3CL protease. J Biol Chem 280(35):31257–31266
18. Mielech AM et al (2014) Nidovirus papain-like proteases: multifunctional enzymes with protease, deubiquitinating and delSfating activities. Virus Res 194:184–190
19. Knoops K et al (2008) SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum. PLoS Biol 6(9):e226
20. Wu C et al (2020) Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B 10(5):766–788
21. Shannon A et al (2020) Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 exonuclease active-sites. Antivir Res 178:104793
22. Yin W et al (2020) Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science 368(6498):1499–1504
23. Mira MA, Froyen M (2020) Structural elucidation of SARS-CoV-2 vital proteins: computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase. J Pharm Anal 10(4):320–328
24. Decoly E et al (2011) Crystal structure and functional analysis of the SARS-coronavirus RNA cap 2′-O-methyltransferase nsp10/nsp16 complex. PLoS Pathog 7(5):e1002059
25. Chen Y et al (2020) Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase. Proc Natl Acad Sci U S A 106(9):3484–3489
26. Ma Y et al (2015) Structural basis and functional analysis of the SARS coronavirus nsp14-nsp10 complex. Proc Natl Acad Sci U S A 112(30):9436–9441
Khan RJ et al (2020) Identification of promising antiviral drug candidates against non-structural protein 15 (NSP15) from SARS-CoV-2: an in silico assisted drug-repurposing study. J Biomol Struct Dyn:1–10

Fan K et al (2004) Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like protease. J Biol Chem 279(2):1637–1642

Thiel V et al (2001) Viral replicase gene products suffice for coronavirus discontinuous transcription. J Virol 75(14):6676–6681

Yang H et al (2003) The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc Natl Acad Sci U S A 100(23):13190–13195

Jin Z et al (2020) Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 582(7813):289–293

Anand K et al (2002) Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain. EMBO J 21(13):3213–3224

Xue X et al (2008) Structures of two coronavirus main proteinases: implications for substrate binding and antiviral drug design. J Virol 82(5):2515–2527

Anand K et al (2003) Coronavirus main proteinase (3CL(pro)) structure: basis for design of anti-SARS drugs. Science 300(5626):1763–1767

Yang H et al (2005) Design of wide-spectrum inhibitors targeting coronavirus main proteinase. PLoS Biol 3(10):e324

Ren Z et al (2013) The newly emerged SARS-like coronavirus HCoV-EMC also has an ‘Achilles’ heel’: current effective inhibitor targeting a 3C-like protease. Protein Cell 4(4):249–250

Wang F et al (2016) Structure of main protease from human coronavirus NL63 insights for wide spectrum anti-coronavirus drug design. Sci Rep 6:22677

Wang H et al (2020) Comprehensive insights into the catalytic mechanism of Middle East respiratory syndrome 3C-like protease and severe acute respiratory syndrome 3C-like protease. ACS Catal 10:5871–5890

Chou KC, Wei DIQ, Zhong WZ (2003) Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. Biochem Biophys Res Commun 308(1):148–151

Jin Z et al (2020) Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Nat Struct Mol Biol 27(6):529–538

Zhang L et al (2020) Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors. Science 368(6480):409–412

Ul Qamar MT et al (2020) Structural basis of SARS-CoV-2 3CL(pro) and anti-COVID-19 drug discovery from medicinal plants. J Pharm Anal

Islam R et al (2020) A molecular modeling approach to identify effective phytochemicals against the main protease of SARS-CoV-2. J Biomol Struct Dyn:1–12

Joshi T et al (2020) In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking. Eur Rev Med Pharmacol Sci 24(24):4529–4536

Joshi RS et al (2020) Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main protease. J Biomol Struct Dyn:1–16

Bhardwaj VK et al (2020) Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors. J Biomol Struct Dyn:1–10

Mittal L et al (2020) Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach. J Biomol Struct Dyn:1–19

Wang J (2020) Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study. J Chem Inf Model 60(6):3277–3286

Gyebi GA et al (2020) Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL(pro)): an in silico screening of alkaloids and terpenoids from African medicinal plants. J Biomol Struct Dyn:1–13

Aanouz I et al (2020) Moroccan medicinal plants as inhibitors against SARS-CoV-2 main protease: computational investigations. J Biomol Struct Dyn:1–9

Umesh et al (2020) Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target. J Biomol Struct Dyn:1–9

Kumar V et al (2020) Withanolide and caffeic acid phenethyl ester are predicted to interact with main protease (Mpro) of SARS-CoV-2 and inhibit its activity. J Biomol Struct Dyn:1–13

Huyhn T, Wang H, Luan B (2020) In silico exploration of the molecular mechanism of clinically oriented drugs for possibly inhibiting SARS-CoV-2's main protease. J Phys Chem Lett 11(11):4413–4420

Kumar D et al (2020) Understanding the binding affinity of noscapines with protease of SARS-CoV-2 for COVID-19 using MD simulations at different temperatures. J Biomol Struct Dyn:1–14

Peele KA et al (2020) Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2: a computational study. Inform Med Unlocked 100545

Ak-Haifaji K, Al-Duhaishawi D, Taskin Tok T (2020) Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2. J Biomol Struct Dyn:1–9

Kandeel M, Al-Nazawi M (2020) Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease. Life Sci 251:117627

Nutho B et al (2020) Why are lopinavir and ritonavir effective against the newly emerged coronavirus 2019? Atomic insights into the inhibitory mechanisms. Biochemistry 59(18):1769–1779

Calligari P et al (2020) Molecular investigation of SARS-CoV-2 proteins and their interactions with antiviral drugs. Viruses 12(4)

Khan RJ et al (2020) Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like protease and 2′-O-ribose methyltransferase. J Biomol Struct Dyn:1–14

Mahanta S et al (2020) Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: an in silico based approach. J Biomol Struct Dyn:1–10

Reiner Z et al (2020) Statins and the COVID-19 main protease: in silico evidence on direct interaction. Arch Med Sci 16(3):490–496

Shah B, Modi P, Sagar SR (2020) In silico studies on therapeutic agents for COVID-19: drug repurposing approach. Life Sci 252:116552

Panche AN, Divan AD, Chandra SR (2016) Flavonoids: an overview. J Nutr Sci 5:47

Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31(2):455–461

Gagnon JK, Law SM, Brooks CL 3rd (2016) Flexible CDOCKER: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49(21):6177–6196

Ruzicka L (1953) The isoprene rule and the biogenesis of terpenic compounds. Experientia 9(10):357–367

Forti S et al (2016) Computational protein-ligand docking and virtual drug screening with the AutoDock suite. Nat Protoc 11(5):905–919

Bowers KJ, E.C, Xu H, Dror RO, Eastwood MP, Gregersen BA, Klepeis JL, Miller BR 3rd et al (2012) MMPBSA.py: an efficient program for end-state thermodynamic integration of changes in free energy of binding. J Chem Theory Comput 8(12):5650–5659

Chen YW, Yiu CB, Wong KY (2020) Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL(pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Res 9:129

Miller ER 3rd et al (2011) MM+PSA.py: an efficient program for end-state free energy calculations. J Chem Theory Comput 7(9):3314–3321

Dafaykan S, Olton AJ (2015) Small-molecule library screening by docking with PyRx. Methods Mol Biol 1263:243–250

Studio D (2016) Dassault systems BIOVIA, Discovery studio modelling environment, release, p. 4

Sobolim J et al (2017) Assessing the efficacy and safety of eravacycline vs. etapamycin in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial. JAMA Surg 152(6):224–232
81. Sabnis N et al (2012) Enhanced solubility and functionality of valrubin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles. Int J Nanomedicine 7:975–983
82. Shabalin DA, Camp JE (2020) Recent advances in the synthesis of imidazoles. Org Biomol Chem 18(21):3950–3964
83. Bell AM et al (2016) Elbasvir/grazoprevir: a review of the latest agent in the fight against hepatitis C. Int J Hepatol 2016:3852126
84. Abramowitz MK, Meyer TW, Hostetter TH (2010) Chapter 18 - the pathophysiology of uremia. In: Himmelfarb J, Sayegh MH (eds) Chronic kidney disease, dialysis, and transplantation, 3rd edn. W.B. Saunders, Philadelphia, pp 251–264

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.